Gelomics is pleased to announce a strategic partnership with Voden Medical, a renowned provider of advanced diagnostic and life science solutions in Italy. Under this agreement, Voden Medical will serve as Gelomics’ exclusive distributor in the Italian market. This partnership, effective January 2025, marks a significant step forward in Gelomics’ mission to bring our innovative 3D cell culture technologies to life science researchers and institutions throughout Europe. Leveraging Voden Medical’s deep expertise and established network in Italy, this collaboration is poised to drive transformative progress in biomedical research and drug development.

“At Gelomics, we believe that groundbreaking science thrives on strong partnerships. Collaborating with Voden Medical allows us to bring our transformative 3D cell culture technologies to the forefront of Italy’s world-class biomedical research landscape. Together, we’re not just delivering innovative tools; we’re fostering a new era of discovery that redefines how drugs are developed and human biology is understood.”

Dr Christoph Meinert, CEO of Gelomics.

About Gelomics

Gelomics is dedicated to revolutionising drug development and biomedical research by enabling the cultivation of human tissue models in vitro. Our mission is to accelerate therapeutic breakthroughs by providing scientists with ethical, cost-effective, and predictive alternatives to animal testing. For more information about Gelomics and our range of products, please visit https://www.gelomics.com.

About Voden Medical

Voden Medical is a leading provider of diagnostic and life science solutions in Italy, specializing in cutting-edge technologies that support the healthcare and research communities. With a strong focus on customer satisfaction and technical expertise, Voden Medical brings innovative solutions to laboratories across the country. For more information, visit www.vodenmedical.com.